Phase 3Not yet recruiting
A study to compare heart failure medicines in one combined pill with usual care. (S005207-229)
A multinational, multicenter, prospective, randomized, open-label, event-driven trial with two parallel arms, to compare the efficacy and safety of Guideline-Directed Medical Therapy (GDMT) with the use of Fixed-Dose Combination (FDC) strategy versus usual care for the management of Heart Failure.
- Sponsor
- Institut De Recherches Internationales Servier IRIS (Industry)
- Enrollment
- 275 planned
- Conditions
- Heart Failure; Heart failure
- Interventions
- Hard-gelatin capsules containing 10/10/50 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/50 mg of Dapagliflozin/Eplerenone; Hard-gelatin capsules containing 10/2.5 mg of Dapagliflozin/Bisoprolol fumarate; Hard-gelatin capsules containing 10/25 mg of Dapagliflozin/Eplerenone; Hard-gelatin capsules containing 10/5 mg of Dapagliflozin/Bisoprolol fumarate; Hard-gelatin capsules containing 10/10/25 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/5/50 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/5/25 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/10 mg of Dapagliflozin/Bisoprolol fumarate
- Ages
- adults, older adults
- Registry
- CTIS2026-526510-90-00
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To evaluate in participants admitted for acute HF the effect of treatment delivered as FDC (Fixed-dose combination) based strategy compared to usual care on HFE (Heart Failure Event) and cardiovascular death
Primary outcomes
- Times to occurrences of total (first and recurrent) HFEs and cardiovascular death
History
Enrollment up to 275
, from 205 to 275
Last registry update
Enrollment up to 205
, from 90 to 205
Registered